Agios Pharmaceuticals reported 3.56 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
AbbVie 23.45 0.51 Sep/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Alnylam Pharmaceuticals 13.17 62.47 Sep/2026
Amgen 18.6 0.53 Sep/2026
Arrowhead Research 39.19 0 Jun/2026
Astellas Pharma 9.57 0.16 Sep/2026
AstraZeneca 24.63 0.71 Sep/2026
Bayer 4.61 0.47 Sep/2026
Biogen 29.15 5.92 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Daiichi Sankyo 18.6 1.54 Sep/2026
Eli Lilly 64.5 31.61 Sep/2026
Exelixis 18.43 0.41 Sep/2026
Gilead Sciences 17.68 4.18 Sep/2026
GlaxoSmithKline 9.72 0.9 Sep/2026
Incyte 54.54 40.08 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Merck 34.36 2.11 Sep/2026
Moderna 27.22 14.51 Jun/2023
Novartis 19.17 3.24 Sep/2026
Novartis 21.54 0.18 Sep/2026
Pfizer 15.2 3.72 Sep/2026
Puma Biotechnology 13.93 44.88 Jun/2024
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sarepta Therapeutics 32.09 22.66 Sep/2026
Vertex Pharmaceuticals 29.35 1.3 Sep/2026